Chapter title |
The Clinical Use of PET/CT in the Evaluation of Melanoma.
|
---|---|
Chapter number | 30 |
Book title |
Molecular Diagnostics for Melanoma
|
Published in |
Methods in molecular biology, January 2014
|
DOI | 10.1007/978-1-62703-727-3_30 |
Pubmed ID | |
Book ISBNs |
978-1-62703-726-6, 978-1-62703-727-3
|
Authors |
Khun Visith Keu, Andrei H Iagaru, Andrei H. Iagaru, Keu, Khun Visith, Iagaru, Andrei H. |
Abstract |
Positron emission tomography combined with computed tomography (PET/CT) has emerged in the last decade as a dominant imaging modality used for staging, monitoring response and surveillance of various cancers, including melanoma. Using 2-deoxy-2-((18)F)fluoro-D-glucose ((18)F-FDG) as the radiopharmaceutical, PET/CT has demonstrated its efficacy and its utility in the management of patients with advanced melanoma. Nonetheless, challenges remain in the early stage evaluation of melanoma and in the development of novel radiotracers to better characterize lesions found on PET/CT. This chapter focuses on the advantages and limitations of this imaging modality in melanoma. We also detail and describe the approach to perform (18)F-FDG PET/CT, the methods to accurately quantify lesions, as well as the pearls/pitfalls of image interpretation. Finally, an overview of preclinical and investigational clinical radiopharmaceuticals is presented. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 5% |
Unknown | 18 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 6 | 32% |
Student > Doctoral Student | 3 | 16% |
Researcher | 3 | 16% |
Professor > Associate Professor | 2 | 11% |
Student > Ph. D. Student | 1 | 5% |
Other | 2 | 11% |
Unknown | 2 | 11% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 47% |
Biochemistry, Genetics and Molecular Biology | 2 | 11% |
Agricultural and Biological Sciences | 2 | 11% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
Neuroscience | 1 | 5% |
Other | 2 | 11% |
Unknown | 2 | 11% |